

Chronic Hepatitis B (CHB) Market Updates : Projected to Attain USD 6.2 billion by 2031

The chronic hepatitis b market was valued at \$4.6 billion in 2021, and is estimated to reach \$6.2 billion by 2031, growing at a CAGR of 3% from 2022 to 2031.

WILMINGTON, DELAWARE , UNITED STATES, April 17, 2024

/EINPresswire.com/ -- According to the report published by Allied Market Research, the global [Chronic Hepatitis B \(CHB\) Market](#) size was estimated at \$4.6 billion in 2021 and is expected to

hit \$6.1 billion by 2031, registering a CAGR of 3.0% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

“

The chronic hepatitis b (CHB) market was valued at \$4.6 billion in 2021, and is estimated to reach \$6.2 billion by 2031, growing at a CAGR of 3% from 2022 to 2031.”

Allied Market Research



□□□□□□□□ □□□□□□□□ □□□□ □□ □□□□□□□□

<https://www.alliedmarketresearch.com/request-sample/A31523>

The global [Chronic Hepatitis B \(CHB\)](#) market undergoes comprehensive analysis, examining Drug Class, Gender, Distribution Channel, and Region. The report offers detailed insights into segments and their sub-segments,

employing tabular and graphical representations. Investors and market players can leverage this breakdown to formulate strategies, focusing on the most lucrative and rapidly growing segments highlighted in the report.

In terms of drug class, the antivirals segment accounted for 87% of the total market revenue in 2021 and is projected to maintain its dominance through 2031. On the other hand, the immune

modulators segment is anticipated to exhibit the highest CAGR of 4.2% during the forecast period.

□□□ □□□□□□□□ □□ □□□ □□□□□

By drug class, the antivirals segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.

By gender, the male segment was the highest contributor to the Chronic Hepatitis B (CHB) Market in 2021.

By distribution channel, the drug stores & retail pharmacies segment was the highest contributor to the market in 2021.

Region wise, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

□□□□□ □□ □□□ □□□□□□□□- <https://www.alliedmarketresearch.com/connect-to-analyst/A31523>

□□□ □□□□□□□□ □□□ □□□□□□□□□□□□□□

This report provides a quantitative analysis of the market segments, current Chronic Hepatitis B Market Trends, estimations, and dynamics of the chronic hepatitis b (chb) market analysis from 2021 to 2031 to identify the prevailing Chronic Hepatitis B Market Opportunity.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces Chronic Hepatitis B Market Analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the chronic hepatitis b (chb) market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global chronic hepatitis b (chb) market trends, key players, market segments, application areas, and market growth strategies.

□□□ □□□□□□ □□□□□□□□

Teva Pharmaceutical Industries Limited

F. Hoffman La Roche, Ltd.

Novartis AG

Zydus Cadila

Viatrix Inc. (Mylan NV)
Cipla Ltd
Bristol Myers Squibb Co.
Merck & Co. Inc.
GlaxoSmithKline (GSK)
Gilead Sciences, Inc.

David Correa
Allied Market Research
+1 5038946022

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/704338303>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.